Watson seeks FDA approval to market rasagiline mesylate tablets

Links shared publicly online about this topic.

822
total visits

Watson seeks FDA approval to market rasagiline mesylate tablets

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market rasagiline mesylate 0.5 and 1.0 mg tablets.

View full resource at news-medical.net

Tags: Diet and Nutrition, Drug, Pharma, FDA, Watson Pharmaceuticals